share_log

Hypera (OTCMKTS:HYPMY) Lifted to "Buy" at The Goldman Sachs Group

Hypera (OTCMKTS:HYPMY) Lifted to "Buy" at The Goldman Sachs Group

Hypera(OTCMKTS：HYPMY)在高盛被提升為“買入”
Defense World ·  2022/10/18 15:12

The Goldman Sachs Group upgraded shares of Hypera (OTCMKTS:HYPMY – Get Rating) from a neutral rating to a buy rating in a research report released on Monday morning, The Fly reports.

據The Fly報道，在週一上午發佈的一份研究報告中，高盛將Hypera(場外交易代碼：HYPMY-GET Rating)的股票評級從中性上調至買入。

Hypera Price Performance

Hypera性價比

Shares of HYPMY stock opened at $8.89 on Monday. Hypera has a 1 year low of $4.63 and a 1 year high of $9.17. The firm has a fifty day moving average price of $8.40 and a 200-day moving average price of $7.96.

HYPMY股票週一開盤報8.89美元。Hypera的一年低點為4.63美元，一年高位為9.17美元。該公司的50日移動均線價格為8.40美元，200日移動均線價格為7.96美元。

Get
到達
Hypera
金絲桃組
alerts:
警報：

Hypera Company Profile

Hypera公司簡介

(Get Rating)

(獲取評級)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Hypera SA在巴西作為一家制藥公司運營。它提供的處方藥有Adacne、Addera、Apri、AmpliumG、請、賽萊他明、Celstone、Celstone Soluspana、Cizax、DECPRAX、衍生CMicro、Micro Drift、Dermol Fusid、Digedrat、雙丙胺、雙丙沙星、雙丙鬆、雙丙鬆、Emprol XR、Flow、Garasone、Halobx、Lipanon、Moon、Lydian、Macrodantin、MaxSulid、MilGamma、Mioflex-A、Nesina、Novotram、oximax、peridid、Perida混懸劑、Predsim、Pressaliv、Quadriderm、Rizi、Rizi、Softalm、acrotz、tinodin、umma和velunid品牌。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on Hypera (HYPMY)
  • Biogen's Stock Pullback Offers a Second Chance
  • Pitch a Tent in Camping World Stock
  • Fisker is Entering a Critical Stage That Could Reward Investors
  • The Bottom Is In For JPMorgan Chase & Co.
  • The Institutions May Cap Gains In Steel Dynamics
  • 免費獲取StockNews.com關於Hypera的研究報告(HYPMY)
  • Biogen的股票回調提供了第二次機會
  • 在露營世界股票中搭起帳篷
  • 菲斯克正在進入一個關鍵階段，這可能會給投資者帶來回報
  • 摩根大通的日子不好過了。
  • 這些機構可能會限制鋼鐵動力領域的收益

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.

接受Hypera Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Hypera和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論